|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
84,190,000 |
Market
Cap: |
10.96(B) |
Last
Volume: |
427,350 |
Avg
Vol: |
426,131 |
52
Week Range: |
$67.31 - $157.19 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 16.7 |
Insider 3/6 Months : 17.3 |
|
Guru Rank Number : 983 |
Guru Rank Value : 0 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
75,225 |
143,757 |
247,027 |
Total Buy Value |
$0 |
$5,942,300 |
$13,295,068 |
$24,257,422 |
Total People Bought |
0 |
2 |
3 |
3 |
Total Buy Transactions |
0 |
2 |
5 |
7 |
Total Shares Sold |
24,096 |
24,096 |
39,096 |
39,954 |
Total Sell Value |
$2,990,141 |
$2,990,141 |
$4,590,941 |
$4,685,252 |
Total People Sold |
6 |
6 |
6 |
6 |
Total Sell Transactions |
6 |
6 |
7 |
8 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Boor Kathryn Jean |
|
|
2024-03-11 |
4 |
S |
$122.93 |
$93,550 |
D/D |
(761) |
7,516 |
|
-7% |
|
Estepan Ian Michael |
Chief Financial Officer |
|
2024-03-08 |
4 |
D |
$123.14 |
$127,450 |
D/D |
(1,035) |
36,164 |
|
- |
|
Arif Bilal |
Chief Tech Ops Officer |
|
2024-03-08 |
4 |
D |
$123.14 |
$58,122 |
D/D |
(472) |
25,222 |
|
- |
|
Brown Ryan Edward |
EVP, General Counsel |
|
2024-03-08 |
4 |
D |
$123.14 |
$110,703 |
D/D |
(899) |
28,688 |
|
- |
|
Rodino-Klapac Louise |
Head of R&D, CSO |
|
2024-03-08 |
4 |
D |
$123.14 |
$111,934 |
D/D |
(909) |
68,073 |
|
- |
|
Wigzell Hans Lennart Rudolf |
|
|
2024-03-08 |
4 |
S |
$122.39 |
$1,848,795 |
D/D |
(15,000) |
22,840 |
|
-5% |
|
Wigzell Hans Lennart Rudolf |
|
|
2024-03-08 |
4 |
OE |
$13.90 |
$208,500 |
D/D |
15,000 |
37,840 |
|
- |
|
Estepan Ian Michael |
Chief Financial Officer |
|
2024-03-07 |
4 |
D |
$120.49 |
$63,378 |
D/D |
(526) |
37,199 |
|
- |
|
Arif Bilal |
Chief Tech Ops Officer |
|
2024-03-07 |
4 |
D |
$120.49 |
$60,968 |
D/D |
(506) |
25,694 |
|
- |
|
Brown Ryan Edward |
EVP, General Counsel |
|
2024-03-07 |
4 |
D |
$120.49 |
$60,968 |
D/D |
(506) |
29,587 |
|
- |
|
Rodino-Klapac Louise |
Head of R&D, CSO |
|
2024-03-07 |
4 |
D |
$120.49 |
$61,691 |
D/D |
(512) |
68,982 |
|
- |
|
Mayo Stephen |
|
|
2024-03-05 |
4 |
S |
$122.96 |
$385,480 |
D/D |
(3,135) |
6,621 |
|
-6% |
|
Brown Ryan Edward |
EVP, General Counsel |
|
2024-03-04 |
4 |
D |
$125.32 |
$217,305 |
D/D |
(1,734) |
30,093 |
|
- |
|
Estepan Ian Michael |
Chief Financial Officer |
|
2024-03-04 |
4 |
D |
$125.32 |
$174,069 |
D/D |
(1,389) |
37,725 |
|
- |
|
Arif Bilal |
Chief Tech Ops Officer |
|
2024-03-04 |
4 |
D |
$125.32 |
$65,417 |
D/D |
(522) |
26,200 |
|
- |
|
Rodino-Klapac Louise |
Head of R&D, CSO |
|
2024-03-04 |
4 |
D |
$125.32 |
$216,553 |
D/D |
(1,728) |
69,494 |
|
- |
|
Wigzell Hans Lennart Rudolf |
|
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,846 |
22,840 |
|
- |
|
Nicaise Claude |
|
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,846 |
18,174 |
|
- |
|
Rodino-Klapac Louise |
Head of R&D, CSO |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
71,222 |
|
- |
|
Rodino-Klapac Louise |
Head of R&D, CSO |
|
2024-03-01 |
4 |
D |
$126.19 |
$98,176 |
D/D |
(778) |
65,222 |
|
- |
|
Boor Kathryn Jean |
|
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,846 |
8,277 |
|
- |
|
Chambers Michael Andrew |
|
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,846 |
8,277 |
|
- |
|
Mayo Stephen |
|
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,846 |
9,756 |
|
- |
|
Brown Ryan Edward |
EVP, General Counsel |
|
2024-03-01 |
4 |
S |
$125.34 |
$250,680 |
D/D |
(2,000) |
31,827 |
|
-1% |
|
Brown Ryan Edward |
EVP, General Counsel |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
33,827 |
|
- |
|
360 Records found
|
|
Page 1 of 15 |
|
|